Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02816398
Other study ID # 01-0012-01
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date January 2014
Est. completion date January 2016

Study information

Verified date June 2016
Source Medtronic Endovascular
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Feasibility clinical study to evaluate the safety and effectiveness of the catheter system for the percutaneous creation of an arteriovenous fistula for patients with end stage renal disease requiring dialysis access.


Recruitment information / eligibility

Status Completed
Enrollment 26
Est. completion date January 2016
Est. primary completion date October 2015
Accepts healthy volunteers No
Gender All
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria: - Patients deemed medically eligible for AV fistula creation per institutional guidelines and/or clinical judgment - Patients diagnosed with chronic kidney disease classification stage IV or V - Adequate quality vein >= 2 mm with confirmed clinically significant outflow based on pre-operative assessment - Adequate quality radial artery >= 2 mm based on pre-operative assessment - Adequate collateral arterial perfusion - Radial artery-adjacent vein proximity < = 1.5 mm - Able to provide informed consent - Able to travel to institution for follow up examination - Able to intraoperatively place an .014" guidewire in artery Exclusion Criteria: - Suspected skin disease - Immunocompromised patients (e.g. HIV positive) - Edema of extremities - Current diagnosis of carcinoma - Pregnancy or currently breast feeding - Diagnosed hypercoaguable state - Active infection - Evidence of vascular disease at target site - Pre-existing vascular disease that could confound study results - Vessel tortuosity or spasm preventing placement of .014" guidewire

Study Design


Related Conditions & MeSH terms


Intervention

Device:
Percutaneous creation of an arteriovenous fistula
Use of catheter system for percutaneous creation of an arteriovenous fistula

Locations

Country Name City State
n/a

Sponsors (2)

Lead Sponsor Collaborator
Medtronic Endovascular Hospital Universitario Dr. Jose E. Gonzalez

Outcome

Type Measure Description Time frame Safety issue
Primary Number of Participants With Sufficient Patency for Clinical Access Arteriovenous fistula is patent as determined by auscultation or ultrasound and eligible for maturation assistance to achieve clinical access flow rate. 6 weeks
Primary Number of Patients Achieving Dialysis Access Arteriovenous fistula is mature and patient has started dialysis using the fistula 6 weeks
Primary Number of Patients on Dialysis Using the Arteriovenous Fistula or Has Adequate Access Flow Rate to Allow Dialysis Arteriovenous fistula is mature or has achieved a minimum clinically acceptable access flow rate as determined by doppler ultrasound assessment to support dialysis 3 months
Secondary Number of Patients Requiring Additional Interventions to Achieve Maturation and Dialysis Access The number of patients requiring additional interventions to achieve maturation and initiation of dialysis. 12 weeks
See also
  Status Clinical Trial Phase
Terminated NCT05056727 - A Study to Evaluate the Effect of Sodium Zirconium Cyclosilicate on Chronic Kidney Disease (CKD) Progression in Participants With CKD and Hyperkalaemia or at Risk of Hyperkalaemia Phase 3
Withdrawn NCT01655186 - A Double-Blind, Randomized, Placebo-Controlled Study Evaluating the Effects of Bardoxolone Methyl on Body Composition in Patients With Stage 4 Chronic Kidney Disease and Type 2 Diabetes Mellitus Phase 2
Completed NCT03481686 - Therapeutic Education of Chronic Renal or Renal Transplant Patient in the Management of EPO Injections N/A
Active, not recruiting NCT03672110 - Slow and Low Start of a Tacrolimus Once Daily Immunosuppressive Regimen Phase 3
Enrolling by invitation NCT02237534 - Lanthanum Versus Calcium Carbonate for Vascular Abnormalities in Patients With CKD and Hyperphosphatemia Phase 4
Completed NCT02126293 - Correction of Zinc Deficiency in Children With Chronic Kidney Disease and Kidney Transplant Phase 3
Terminated NCT01533545 - Effect of Epinephrine on Systemic Absorption of Mepivacaine in Uremic Patients N/A
Completed NCT03280615 - Omega 3 Fatty Acids in Patients With Chronic Renal Disease Phase 3
Completed NCT04498156 - Survey of Patient and Physician Awareness and Values to the Diagnosis and Treatment of Reduced Kidney Function (Chronic Kidney Disease) in Patients With High Blood Sugar Level (Type 2 Diabetes) (AWARE-CKD in T2D)
Recruiting NCT04020328 - Leflunomide Plus Low Dose Corticosteroid in Immunoglobulin A (IgA) Nephropathy With Renal Insufficiency Phase 4
Recruiting NCT06366529 - Explore New Magnetic Resonance Technology in Assessment of Renal Dysfunction
Active, not recruiting NCT04876963 - HOLT-ED: Holter-monitoring in End-stage Renal Disease
Completed NCT03836508 - Effect of Dialysis Membranes on Inflammatory and Immune Processes in Hemodialysis N/A
Completed NCT03250715 - Effects of Low Level Laser Therapy on Functional Capacity and DNA Damage of Patients With Chronic Kidney Failure N/A
Completed NCT03577249 - Biological Effects of Citrate-buffered Solutions on Dialysis Efficiency and Systemic Inflammation Phase 2/Phase 3
Completed NCT01975818 - Maintenance Treatment of Anemia Associated With Chronic Kidney Disease (CKD) in Hemodialysis Subjects on Epoetin Alfa / Beta Treatment Versus BAY85-3934 Phase 2
Active, not recruiting NCT05766644 - App-based Education Program for CKD N/A
Active, not recruiting NCT02791880 - Acute Kidney Injury Genomics and Biomarkers in TAVR Study
Recruiting NCT02947750 - Neurovascular Transduction During Exercise in Chronic Kidney Disease Phase 2
Terminated NCT02286258 - Validation of New Markers of Glomerular Filtration Rate: Dota Gadolinium and Calcium EDTA (MultiGFR) Phase 1/Phase 2